Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Participants will receive once-weekly cagrilintide subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Participants will receive once-weekly semaglutide subcutaneously.
Name:
Placebo
Type:
DRUG
Description:
Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Primary Outcomes
Measure:
Relative change in body weight
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Measured in percentage (%).
Measure:
Achievement of ≥5% weight reduction
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Measured as count of participant.
Trial Information
NCT ID
NCT06388187
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025